Rapport Therapeutics (NASDAQ:RAPP) Director John Maraganore Acquires 9,411 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director John Maraganore bought 9,411 shares of the business’s stock in a transaction dated Thursday, October 22nd. The stock was acquired at an average cost of $26.45 per share, for a total transaction of $248,920.95. Following the completion of the acquisition, the director directly owned 9,411 shares in the company, valued at approximately $248,920.95. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Rapport Therapeutics Trading Up 5.9%

RAPP stock opened at $26.53 on Friday. The company has a fifty day moving average price of $39.44 and a 200 day moving average price of $39.02. Rapport Therapeutics, Inc. has a 12 month low of $23.75 and a 12 month high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). Analysts forecast that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RAPP has been the subject of several recent research reports. Raymond James Financial reiterated a “strong-buy” rating and set a $86.00 target price on shares of Rapport Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of Rapport Therapeutics in a research report on Tuesday. Guggenheim boosted their price target on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Finally, BTIG Research increased their price objective on Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $68.36.

More Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The candidate produced statistically significant placebo-adjusted improvements in YMRS and CGI-BP mania-severity scores. Rapport plans to begin Phase 3 trials, potentially expanding RAP-219’s commercial opportunity beyond epilepsy. Rapport Therapeutics Announces Positive Topline Results
• Positive Sentiment: Analysts increased or maintained bullish valuations. JonesTrading raised its target to $82, while BTIG reportedly lifted its target to $89. Raymond James raised its target to $86, and HC Wainwright reaffirmed its Buy rating. The consensus target is approximately $68.36, well above recent trading levels. BTIG price target increase
• Positive Sentiment: Company insiders made substantial open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while four directors purchased an additional 52,594 shares. The combined purchases were worth approximately $1.57 million and may signal management confidence following the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s move toward Phase 3 is an important milestone, but investors still face clinical, regulatory, financing, and commercialization uncertainty typical of a clinical-stage biotechnology company.
• Negative Sentiment: The clinical results may have been less decisive than some investors expected. Reports indicated that portions of the data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport also remains unprofitable; its latest quarterly loss exceeded analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. Rapport bipolar data report

Institutional Investors Weigh In On Rapport Therapeutics

Several hedge funds have recently modified their holdings of RAPP. TRV GP V LLC purchased a new position in Rapport Therapeutics in the 2nd quarter valued at $261,709,477. ARCH Venture Management LLC acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $155,376,512. BlackRock Inc. acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter worth $112,500,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $74,360,823. Finally, TRV GP VI LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at about $40,387,314.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.